Milestone Pharmaceuticals, Inc.

Are you attending the Global CVCT - Cardiovascular Clinical Trialists Forum in Washington D.C. from December 9 – 11?        We will be presenting encore data on etripamil, an investigational new drug from the NODE-303 Phase 3 trial in PSVT and the ReVeRA study in AFib-RVR.   Members of our leadership team, including David Bharucha, MD, PhD and Anita Holz, MSN, CRNP, will be in attendance.        We look forward to seeing you there!      #PSVT #SVTAwareness #Arrhythmia #AFib #CVCT2024 

Living with #SVT, also referred to as PSVT, can feel like riding an unpredictable rollercoaster of rapid heartbeats and sudden symptoms. For many, like Dana, a real SVT patient, the journey to a diagnosis took years. She courageously shares her story to raise awareness and reminds us that no one should feel alone in their heart health journey. ️ Stories like Dana’s fuel our commitment to creating solutions that support patients in managing their condition with confidence. Let’s keep pushing for change together. Learn more here about Dana's journey and others who are living with SVT: https://lnkd.in/eC36G6nM #SVTAwareness #PSVT #HeartHealth #PatientStories 

We are looking forward to participating in the Piper Sandler 36th Annual Healthcare Conference from December 3 – 5, in New York City.    Our CEO, Joe Oliveto, and Chief Commercial Officer, Lorenz Muller, will join Ted Tenthoff of Piper Sandler for an insightful fireside chat on Wednesday, December 4 from 10:30-10:55 AM ET.    Read more about our upcoming presentation here: https://lnkd.in/eaxU9rXC   #PSVT #SVTAwareness #Arrhythmia #PiperSandler 

What is #SVT?    Supraventricular tachycardia (SVT), also referred to as PSVT, is a heart condition that leads to episodes of a fast, regular heartbeat that starts and stops without warning. It affects approximately 2 million people in the U.S. At Milestone Pharmaceuticals, we are committed to raising awareness about SVT and its effect on the lives of those impacted by it.  Learn more about SVT here: https://lnkd.in/dpEqC7Fb   #SVTAwareness #PSVT #HeartHealth 

See you next year at #AHA25 in New Orleans from November 8 – 10, 2025. We had a fantastic time at the American Heart Association Scientific Sessions 2024, connecting with industry leaders and gaining insights to drive innovation in cardiovascular care. We’re looking forward to continuing the conversations and collaborations next year. We hope to see you there! #PSVT #SVTAwareness #Arrhythmia  

This past weekend, Nihar Desai, MD, MPH, Associate Professor, Yale School of Medicine, delivered a moderated digital poster presentation at the American Heart Association Scientific Sessions 2024 -- Frequency and Patterns of Paroxysmal Supraventricular Tachycardia Episodes Among Patients Opting For Acute Drug Treatment: Analysis of the NODE-303 Open-Label Etripamil Trial. The poster is available here: https://lnkd.in/eB2qheYY   #AHA24 #PSVT #SVTAwareness #Arrhythmia 

Will you be attending the American Heart Association Scientific Sessions in Chicago from November 16 – 18?     We look forward to sharing data on etripamil, an investigational new drug, from the NODE-303 Phase 3 trial in paroxysmal supraventricular tachycardia (PSVT). This Moderated Digital Poster 23 will be presented by Nihar Desai, MD, MPH, Associate Professor, Yale School of Medicine on Sunday, November 17 from 11:40-11:45 AM CT during “The Return of Antiarrhythmic Drug Therapy: A New Age with New Therapeutics” session.     We look forward to meaningful discussions and making connections at #AHA24 that will drive heart health innovation forward. Join members of our leadership team in Chicago, including David Bharucha, MD, PhD, Lorenz Muller, Anita Holz, MSN, CRNP, Rick Sherwood MD, James Nunez, PharmD., BCPS, and Kim Callahan Fox, and let us know if you are planning to attend in the comments!     #PSVT #SVTAwareness #Arrhythmia 

Today, we reported our financial results from the Third Quarter of 2024. Learn more about these results and recent program updates here: https://lnkd.in/eB_ch-fv

We are excited to announce that we are #hiring an Associate Director, Chemistry Manufacturing & Controls. This role can be filled in Montreal, Canada; Charlotte, NC; or as a hybrid remote employee. If you or someone in your network may be interested, please apply today.    https://lnkd.in/eRZ_qGWf   #MilestonePharmaceuticals #CareerOpportunities #PharmaceuticalJobs 

Attending the Cardiology Advanced Practice Providers (CAPP) conference in Las Vegas from October 17-20?     Join our team, including Muhammad Sheikh, PharmD, who will be presenting encore posters on etripamil, an investigational new drug from the NODE-303 Phase 3 trial in paroxysmal supraventricular tachycardia (PSVT) and the ReVeRA study in AFib-RVR.      Muhammad Sheikh will be at the CardioAPP Posters and Prosecco session, in Red Rock A-C on October 18th from 5:45-6:45PM PDT, where these presentations will be displayed and discussed.    #PSVT #SVTAwareness #Arrhythmia #AFib